Search Jim Cramer's "Mad Money" trading recommendations using our exclusive "Mad Money" Stock Screener.
NEW YORK ( TheStreet) -- Never get too negative or you may get caught on the wrong side of the trade, Jim Cramer said on Mad Money Wednesday. As today's snap-back rally proved, eventually the sellers get done selling.
That surely was the base with Bed Bath & Beyond (BBBY) . The stock had fallen some 20% ahead of earnings, culminating with an analyst downgrade just yesterday. But Bed Bath never got the negativity memo, and instead delivered a three-cents-a-share earnings beat on strong same-store sales. Sales of Bed Bath closed up over 7% by the close.
Must Read: 10 Stocks Carl Icahn Loves in 2014
Cramer also called out the Citizens Financial (CFG) initial public offering, which opened at $21.50 a share only to drop like a stone before the rational minds took over, sending those shares up for a 7% gain on the day.
With oil prices down 12% over the past three months, Cramer said no one is thinking about the positives, like consumers with more money to spend and companies spending less on packaging and shipping. Yet, today stocks like Chipotle Mexican Grill (CMG) , Walt Disney (DIS) and Costco (COST) were all able to rally because consumers have more money to spend. Additionally, stocks like Sherwin-Williams (SHW) , a huge user of natural gas, also rallied as their costs continue to decline.
That's why investors always need to be prepared for when common sense returns to the market, Cramer concluded, because when it does, a stock's fortunes can turn on a dime.
Exciting Biotech Stocks
What's the most exciting portion of the health care industry? Cramer said that without a doubt it's biotech. He noted that his "four horsemen" of Celgene (CELG) , Regeneron (REGN) , Biogen Idec (BIIB) and Gilead Sciences (GILD) continue to soar higher on new drugs, new approvals and new hope for patients.
Just today, Celgene received approval for Otezla, a treatment for skin psoriasis, news that sent shares up a quick 3%. Cramer said not only is this approval a win for Celgene as a product, but it also makes the company stronger by diversifying its product portfolio.
Also in the news today, Acorda Therapeutics (ACOR) , another Cramer fave, which was up an astounding 28% after it announced a $525 million acquisition to help strengthen its product portfolio.
Is more consolidation coming to the biotech space? It's likely, Cramer said, and that gives investors just one more reason to love this group of cutting-edge companies.
Global Payments: Green Dot and Blackhawk Network
For the next installment of his "Global Payments" series, Cramer looked into the fastest-growing segment of the payment business, prepaid cards. Cramer said prepaid cards include everything from prepaid debit and credit cards to loyalty and gift cards as well.
Prepaid cards now account for 5% of all retail spending in the U.S. Cramer noted that parents love them for their teenagers but they also come in handy for aging parents. Merchants also love prepaid options because they get paid upfront and avoid transaction charges later on.
Cramer said Green Dot (GDOT) is essentially a high-tech bank that offers its prepaid cards at some 90,000 retail locations, many of them Wal-Mart (WMT) . Green Dot shares popped 24% today after it was announced that Wal-Mart will roll out the company's GoBank checking account products nationwide. Cramer said he'd be a buyer of Green Dot under $20 a share.
Cramer said his favorite in the space, however, is Blackhawk Network Holdings (HAWK) , a company that manages gift cards for over 600 retailers, processing $10 billion a year worth of transactions. Blackhawk is more diversified than Green Dot, Cramer noted, but he'd also wait for a pullback to purchase this stock.
Executive Decision: Marty Mucci
For his "Executive Decision" segment, Cramer spoke with Marty Mucci, president and CEO of payroll processor Paychex (PAYX) , which today announced a penny-a-share earnings beat on better-than-expected revenue.
Mucci said that Paychex has a lot going in its favor. His company continues to be a solid performer, it has solid financials with over $1 billion in cash, they offer a nice dividend yield and have strong momentum going into their new fiscal year.
When asked about that momentum, Mucci said in the U.S. the company is seeing lots of new business from referrals and partners, while in Germany Paychex has made acquisitions to double its size in that country. Mucci also noted that Brazil is off to a good start, but Paychex has no plans to spread itself too thin as the biggest opportunity still lies in the U.S.
Turning to the hot topic of the Affordable Care Act, Mucci said the new rules are both a blessing and a curse. Companies are indeed skittish about hiring, but all of the confusion usually means companies are more likely to turn to Paychex for help.
Cramer said that Paychex remains a buy.
Cramer was bearish on Chart Industries (GTLS) .
Am I Diversified?
In the "Am I Diversified" segment, Cramer spoke with callers and responded to tweets sent via Twitter to @JimCramer to see if investors' portfolios have what it takes for today's markets.
The first portfolio included Visa (V) , Boeing (BA) , Altria (MO) , TAL International (TAL) and Healthcare REIT (HCN) .
Cramer said he really liked this portfolio.
Cramer also blessed this portfolio as properly diversified.
Cramer said he was also a fan of this portfolio's diversification.
This portfolio made for a four perfectly diversified callers in a row.
To watch replays of Cramer's video segments, visit the Mad Money page on CNBC.
To sign up for Jim Cramer's free Booyah! newsletter with all of his latest articles and videos please click here.
-- Written by Scott Rutt in Washington, D.C.
To email Scott about this article, click here: Scott RuttFollow Scott on Twitter @ScottRutt or get updates on Facebook, ScottRuttDC